News
ABBV
223.67
-1.66%
-3.78
AbbVie price target lowered to $233 from $248 at BofA
TipRanks · 1d ago
AbbVie (ABBV) Receives a Buy from Scotiabank
TipRanks · 1d ago
AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something
Barchart · 1d ago
AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges
TipRanks · 1d ago
Weekly Report: what happened at ABBV last week (1208-1212)?
Weekly Report · 1d ago
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Seeking Alpha · 2d ago
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
PR Newswire · 2d ago
Guru Fundamental Report for ABBV
NASDAQ · 2d ago
Invesco Charter Fund Q3 2025 Portfolio Positioning And Performance Highlights
Seeking Alpha · 2d ago
Healthcare Dashboard For December And Focus On PJP
Seeking Alpha · 2d ago
AbbVie’s New Study on Parkinson’s Treatment: What Investors Need to Know
TipRanks · 2d ago
AbbVie’s Pediatric Kidney Disease Study Update: Implications for Investors
TipRanks · 2d ago
AbbVie’s Venetoclax Study for AML: Key Insights for Investors
TipRanks · 2d ago
AbbVie’s Phase III CLL Study: A Potential Game-Changer in Cancer Treatment
TipRanks · 2d ago
AbbVie’s Venetoclax Study Completion: Implications for CLL Treatment and Market Dynamics
TipRanks · 2d ago
AbbVie’s Latest Study Sheds Light on Vitiligo Burden in China
TipRanks · 2d ago
How AbbVie’s Capital-Light ABBV-230 Deal Reshape At AbbVie (ABBV) Has Changed Its Investment Story
Simply Wall St · 3d ago
My Top 3 Healthcare Stocks to Buy in 2026
The Motley Fool · 3d ago
Eli Lilly: The Right Long-Term Strategy
Seeking Alpha · 3d ago
Lenz drops nearly 30% after FDA’s FAERS finds retinal tear
TipRanks · 4d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).